Compare Transocean Ltd (RIG) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Transocean Ltd vs Viatris Inc — how do they compare? Transocean Ltd trades at $5.74 (market cap $6.43B), while Viatris Inc trades at $16.45 (market cap $19.09B). The key difference: Viatris Inc is far larger — about 3× Transocean Ltd's market cap, and Viatris Inc pays a 2.89% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals.
| RIG | VTRS | |
|---|---|---|
Market Cap | $6.43B | $19.09B |
Sector | Technology | Health |
52-Week High | $7.58 | $17.86 |
52-Week Low | $3.08 | $9.49 |
Enterprise Value | $11.04B | $31.21B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Transocean (RIG) trades at $5.76, down 1.54% today, with a bearish technical signal despite recent earnings beat. The company shows improving operational cash flow ($995M in 2026) and secured a $300M contract with ONGC, but faces challenges with negative net income margins (-40.24%) and high debt levels. Analyst sentiment is mixed with 39% buy ratings amid ongoing profitability concerns.
RIG presents a high-risk opportunity with improving contract backlog and cash flow generation potential offset by substantial debt burden and inconsistent earnings performance. Investors should weigh the company's exposure to volatile oil prices against its position in the tightening deepwater drilling market.
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
